Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2012

View Archived Issues

Rilotumumab does not improve efficacy of combination therapy in prostate cancer trial

Cixutumumab and ramucirumab studied in metastatic castration-resistant prostate cancer

FDA grants orphan drug status to Del Mar Pharmaceuticals product

Magnetic resonance techniques detect metabolic biomarker of low-grade glioma

Intellect Neurosciences provides pipeline update

Novo Nordisk completes phase I trial of novel oral insulin

Prima BioMed begins enrollment in CANVAS study

Merck KGaA claims new ALK5 inhibitors

Brazilian university patents new products with anticancer potential

Bayer Schering designs novel activators of soluble guanylate cyclase

OGX-427 shows signs of efficacy in phase II trial

Phase II trial assesses RO-4929097 in prostate cancer

Alpharadin available through new expanded access program

Pfizer designs novel liver X receptor modulators

Phase II GFT-505 study meets all efficacy objectives

Clinuvel Pharmaceuticals files MAA for erythropoietic protoporphyria treatment

Novel beta1-adrenoceptor ligands synthesized in U.K.

Novel PI3K inhibitors disclosed by Novartis

FDA accepts IND for Ziopharm product

FDA lifts partial clinical hold on hepatitis C therapy

FDA advisory committee sets date to review Marqibo NDA

Biogen Idec and Sobi release details of revised hemophilia program agreement

Oryzon choses drug candidate to begin preclinical testing for Huntington's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...